Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Background A significant portion of breast cancer patients treated in the neoadjuvant setting does not achieve a pathological complete response (pCR) and has an increased risk of relapse after surgery. The current lack of reliable predictors of response to guide patient therapy in clinical practice requires the identification of predictive biomarkers that could discriminate between responders and non-responders. The purpose of this study was to...